Cerebrovascular Disease in COVID-19

References

1. 1.↵
   1. Phelan AL,
   2. Katz R,
   3. Gostin LO

   . The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA 2020 Jan 30. [Epub ahead of print] doi:10.1001/jama.2020.1097 pmid:31999307

   CrossRefPubMed
2. 2.↵
   1. Zhou F,
   2. Yu T,
   3. Du R, et al

   . Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62 doi:10.1016/S0140-6736(20)30566-3 pmid:32171076

   CrossRefPubMed
3. 3.↵
   1. Kanne JP,
   2. Little BP,
   3. Chung JH, et al

   . Essentials for radiologists on COVID-19: an update—radiology scientific expert panel. Radiology 2020 Feb 27. [Epub ahead of print] doi:10.1148/radiol.2020200527 pmid:32105562

   CrossRefPubMed
4. 4.↵
   World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). February 16–24, 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed April 15, 2020
5. 5.↵
   1. Mao L,
   2. Jin H,
   3. Wang M, et al

   . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020 Apr 10. [Epub ahead of print] doi:10.1001/jamaneurol.2020.1127 pmid:32275288

   CrossRefPubMed
6. 6.↵
   1. Helms J,
   2. Kremer S,
   3. Merdji H, et al

   . Correspondence: neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020 Apr 15. [Epub ahead of print] doi:10.1056/NEJMc2008597 pmid:32294339

   CrossRefPubMed
7. 7.↵
   1. Thachil J,
   2. Tang N,
   3. Gando S, et al

   . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023–26 doi:10.1111/jth.14810 pmid:32338827

   CrossRefPubMed
8. 8.↵
   1. Rosário C,
   2. Zandman-Goddard G,
   3. Meyron-Holtz EG, et al

   . The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013;11:185 doi:10.1186/1741-7015-11-185 pmid:23968282

   CrossRefPubMed
9. 9.↵
   1. Nayer A,
   2. Ortega L

   . Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 2014;3:9–17 doi:10.12860/jnp.2014.03 pmid:24644537

   CrossRefPubMed
10. 10.↵
    1. Zhang Y,
    2. Xiao M,
    3. Zhang S

    . Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e38 doi:10.1056/NEJMc2007575 pmid:32268022

    CrossRefPubMed
11. 11.↵
    1. Hoffmann M,
    2. Kleine-Weber H,
    3. Schroeder S, et al

    . SARS-CoV-2 entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.e8 doi:10.1016/j.cell.2020.02.052 pmid:32142651

    CrossRefPubMed
12. 12.↵
    1. Clerkin KJ,
    2. Fried JA,
    3. Raikhelkar J, et al

    . Coronavirus disease 2019 (Covid-19) and cardiovascular disease. Circulation 2020 Mar 21. [Epub ahead of print] doi:10.1161/CIRCULATIONAHA.120.046941 pmid:32200663

    CrossRefPubMed
13. 13.↵
    1. Wang D,
    2. Hu B,
    3. Hu C, et al

    . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020 Feb 7. [Epub ahead of print] doi:10.1001/jama.2020.1585 pmid:32031570

    CrossRefPubMed
14. 14.↵
    1. Libby P,
    2. Loscalzo J,
    3. Ridker P, et al

    . Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 2018;72:2071–81 doi:10.1016/j.jacc.2018.08.1043 pmid:30336831

    FREE Full Text